Connor Clark & Lunn Investment Management Ltd. Sells 81,830 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Connor Clark & Lunn Investment Management Ltd. lessened its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 46.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 94,225 shares of the company’s stock after selling 81,830 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Y-mAbs Therapeutics were worth $1,239,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its holdings in Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after purchasing an additional 3,416 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Y-mAbs Therapeutics during the third quarter worth $178,000. Caxton Associates LP bought a new stake in shares of Y-mAbs Therapeutics in the first quarter valued at about $306,000. Principal Financial Group Inc. acquired a new position in shares of Y-mAbs Therapeutics in the third quarter valued at about $267,000. Finally, Price T Rowe Associates Inc. MD increased its position in Y-mAbs Therapeutics by 8.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after acquiring an additional 1,657 shares during the period. Institutional investors and hedge funds own 70.85% of the company’s stock.

Insider Activity at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 30,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.97, for a total transaction of $389,100.00. Following the sale, the insider now owns 67,681 shares of the company’s stock, valued at $877,822.57. This trade represents a 30.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 22.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms have issued reports on YMAB. Oppenheimer began coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective for the company. BMO Capital Markets reduced their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Friday, November 15th. Morgan Stanley cut their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Tuesday, August 13th. Finally, Wedbush restated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.38.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB opened at $10.77 on Wednesday. Y-mAbs Therapeutics, Inc. has a 52-week low of $5.31 and a 52-week high of $20.90. The firm has a market cap of $482.39 million, a price-to-earnings ratio of -20.07 and a beta of 0.68. The business’s fifty day moving average is $13.64 and its 200-day moving average is $12.83.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the prior year, the firm earned ($0.18) EPS. As a group, research analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.64 EPS for the current fiscal year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.